Late-night salivary cortisol and cortisone should be the initial screening test for Cushing's syndrome.

Cushing’s syndrome salivary cortisol salivary cortisone screening

Journal

Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413

Informations de publication

Date de publication:
01 Jul 2022
Historique:
received: 18 05 2022
accepted: 07 06 2022
pubmed: 8 6 2022
medline: 8 6 2022
entrez: 7 6 2022
Statut: epublish

Résumé

Endogenous Cushing's syndrome (CS) poses considerable diagnostic challenges. Although late-night salivary cortisol (LNSC) is recommended as a first-line screening investigation, it remains the least widely used test in many countries. The combined measurement of LNSC and late-night salivary cortisone (LNS cortisone) has shown to further improve diagnostic accuracy. We present a retrospective study in a tertiary referral centre comparing LNSC, LNS cortisone, overnight dexamethasone suppression test, low-dose dexamethasone suppression test and 24-h urinary free cortisol results of patients investigated for CS. Patients were categorised into those who had CS (21 patients) and those who did not (33 patients). LNSC had a sensitivity of 95% and a specificity of 91%. LNS cortisone had a specificity of 100% and a sensitivity of 86%. With an optimal cut-off for LNS cortisone of >14.5 nmol/L the sensitivity was 95.2%, and the specificity was 100% with an area under the curve of 0.997, for diagnosing CS. Saliva collection is non-invasive and can be carried out at home. We therefore advocate simultaneous measurement of LNSC and LNS cortisone as the first-line screening test to evaluate patients with suspected CS.

Identifiants

pubmed: 35671282
doi: 10.1530/EC-22-0050
pii: EC-22-0050
pmc: PMC9254321
doi:
pii:

Types de publication

Journal Article

Langues

eng

Auteurs

Ramjan Sanas Mohamed (RS)

Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK.

Biyaser Abuelgasim (B)

Imperial College School of Medicine, Department of Biochemistry, Imperial College Healthcare NHS Trust, London, UK.

Sally Barker (S)

Imperial College School of Medicine, Department of Biochemistry, Imperial College Healthcare NHS Trust, London, UK.

Hemanth Prabhudev (H)

Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK.

Niamh M Martin (NM)

Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK.
Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.

Karim Meeran (K)

Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK.
Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.

Emma L Williams (EL)

Department of Biochemistry, Imperial College Healthcare NHS Trust, London, UK.

Sarah Darch (S)

Department of Biochemistry, Imperial College Healthcare NHS Trust, London, UK.

Whitlock Matthew (W)

Department of Biochemistry, Imperial College Healthcare NHS Trust, London, UK.

Tricia Tan (T)

Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK.
Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.

Florian Wernig (F)

Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK.

Classifications MeSH